Tykerb® (Lapatinib): Comparative data have shown that lapatinib based regimens are less effective than trastuzumab based regimens for metastatic breast cancer in certain settings

Kadar pengguna: 2 / 5

bintang aktifbintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 

Date: 04 April 2014

Description: A Direct Healthcare Professional Communication (DHPC) has been issued to inform healthcare professionals of comparative data showing that lapatinib-based regimens are less effective than trastuzumab-based regimens in certain settings. Tykerb®, a kinase inhibitor, is indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Prescribers are reminded that Tykerb® should not be prescribed in combination with capecitabine unless patients have received prior therapy that must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Please refer to the DHPC for more details.

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

Image   Image   Image   Image  

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Rabu 27 Mac 2024, 22:44:22.
© Copyright 2023 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Search